Chronic therapies to treat blood sugar levels and heart conditions have dominated the growth charts in the Rs 1.3-trillion Indian pharma market for a long time.
Read more at: https://www.business-standard.com/article/companies/dermatology-is-the-new-growth-king-in-the-pharma-sector-119040800531_1.html
The growth trajectory for the Indian pharmaceutical industry is likely to be moderate at eight-10 per cent over FY2018 to FY2021, on the back of healthy demand from the domestic market given increasing spend on healthcare along with improving access.
Read more : : http://www.expressbpd.com/pharma/latest-updates/indian-pharma-sector-growth-to-moderate-at-8-10-cagr-over-fy2018-21-icra/409078/
India's biologics market is set for robust growth in 2019 driven by biosimilars production despite ongoing reputational challenges, shows new data from CPhI.
Read more : http://www.expressbpd.com/pharma/latest-updates/india-to-be-one-of-the-worlds-fastest-growing-bio-hubs-in-2019-cphi/409213/
The country's pharmaceutical exports rose by 11 per cent to USD 19.2 billion in 2018-19, mainly driven by higher demand in regions such as North America and Europe, as per a commerce ministry data. The pharma exports in 2017-18 stood at USD 17.3 billion and USD 16.7 billion in the previous fiscal.
Read more : https://www.moneycontrol.com/news/business/economy/pharmaceutical-exports-rise-11-to-19-2-bn-in-2018-19-3875211.html
Veeda Clinical Research Pvt. Ltd., India's leading independent CRO, is pleased to announce that Bureau Veritas has awarded the ISO 27001:2013 Certification to Veeda Clinical Research thereby certifying the compliance of the company's Information Security Management System (ISMS) with the required international standards.
Read more : https://www.prnewswire.com/in/news-releases/veeda-clinical-research-achieves-iso-27001-2013-certification-validating-the-quality-of-its-information-security-management-system-823584498.html